This case highlights an exceptionally rare instance of nivolumab-induced limbic encephalitis in a patient with GC. While our patient recovered spontaneously after drug discontinuation without corticosteroids, the key clinical implication is that new-onset cognitive decline in elderly patients receiving ICIs should not be misattributed to dementia progression. Early recognition of neurological immune-related adverse events is essential, as continued ICI therapy in unrecognized cases may result in irreversible or even fatal outcomes.
SUMIYOSHI et al. (Wed,) studied this question.